| 臺大學術典藏 |
2020-05-26T09:26:40Z |
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6
|
Chih-Hsin Yang;Kim M;Massey D;Gibson N;Hirsh V;O'Byrne K;Yamamoto N;Mok T;Schuler M;Hou M;Li W;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non?�Small Cell Lung Cancer?�A Meta-Analysis
|
Chih-Hsin Yang;Mok T;Gebski V;Links M;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Links M; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:33Z |
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non?�Small-Cell Lung Cancer
|
Park K.;Puri T;Orlando M;Han B;Mok T;Chih-Hsin Yang; CHIH-HSIN YANG; Mok T; Han B; Orlando M; Puri T; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:32Z |
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
|
O?�Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG; Schuler M; Mok T; Yamamoto N; Huang Y; Lu S; Hu C.-P; Feng J; Sequist L.V; Hirsh V; Wu Y.-L; Chih-Hsin Yang;Lungershausen J;M?rten A;Massey D;Zhou C;Geater S.L;O??Byrne K;Yamamoto N;Mok T;Schuler M;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Hirsh V;Wu Y.-L |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis
|
Chih-Hsin Yang;Mok T;Gralla R.J;Herbst R.S;Gebski V;Links M;Cooper W;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst R.S; Gralla R.J; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:28Z |
The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer
|
Chih-Hsin Chih-Hsin Yang;Mok T;Gralla R;Gebski V;Davies L;Asher R;Mitsudomi T;Fukuoka M;Rosell R;Sequist L;Wu Y.L;Marschner I;Lord S;Lee C.K; Lee C.K; Lord S; Marschner I; Wu Y.L; Sequist L; Rosell R; Fukuoka M; Mitsudomi T; Asher R; Davies L; Gebski V; Gralla R; Mok T; Chih-Hsin CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:27Z |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
|
Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:21Z |
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
|
Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer
|
Woodford R;Loh Y;Lee J;Cooper W;Marschner I;Lewis C.R;Millward M;Lord S;Gralla R.J;Chih-Hsin Yang;Mok T;Lee C.K.; Woodford R; Loh Y; Lee J; Cooper W; Marschner I; Lewis C.R; Millward M; Lord S; Gralla R.J; CHIH-HSIN YANG; Mok T; Lee C.K. |
| 臺大學術典藏 |
2020-05-26T09:26:16Z |
The impact of smoking on the effectiveness of immune checkpoint inhibitors ??a systematic review and meta-analysis
|
Mok T; Lee C.K.; CHIH-HSIN YANG; Stockler M; Gralla R; Kasherman L; Marschner I; Lord S.J; Lee K.W.C; Lee K.W.C;Lord S.J;Kasherman L;Marschner I;Stockler M;Gralla R;Chih-Hsin Yang;Mok T;Lee C.K. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Chia-Chi Lin; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; Yang C.-H; Mok T. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
Chia-Chi Lin; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.; Srimuninnimit V; Ahn M.-J; Mok T; Kang J.H; Yang J.C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 臺大學術典藏 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Shaw A.T.; Passos V.Q.; Chen Z.; Viraswami-Appanna K.; Spigel D.R.; Scagliotti G.V.; Mok T.; Su W.-C.; Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Nishio M.;Felip E.;Orlov S.;Park K.;Chong-Jen Yu;Tsai C.-M.;Cobo M.;Mckeage M.;Su W.-C.;Mok T.;Scagliotti G.V.;Spigel D.R.;Viraswami-Appanna K.;Chen Z.;Passos V.Q.;Shaw A.T. |
| 國立成功大學 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Nishio, M.;Felip, E.;Orlov, S.;Park, K.;Yu, C.-J.;Tsai, C.-M.;Cobo, M.;McKeage, McKeage M.;Su, W.-C.;Mok, T.;Scagliotti, G.V.;Spigel, D.R.;Viraswami-Appanna, K.;Chen, Z.;Passos, V.Q.;Shaw, A.T. |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
|
Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新 |
| 國立臺灣大學 |
2015 |
Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
|
Mok, T.; Saijo, N.; Thongprasert, S.; Yang, J. C. -H.; Wu, Y. -L.; Young, H.; Haddad, V.; Jiang, H.; Fukuoka, M.; 楊志新 |
| 國立臺灣大學 |
2015 |
Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu, Y. -L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. -M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, M.; Hirsh, V.; Yamamoto, N.; O'Byrne, K.; Mok, T.; Massey, D.; Maerten, A.; Yang, J. C. -H.; 楊志新 |
| 臺大學術典藏 |
2014 |
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: Results of an International expert panel meeting of the Italian association of thoracic oncology
|
Gridelli C;De Marinis F;Cappuzzo F;Di Maio M;Hirsch F.R;Mok T;Morgillo F;Rosell R;Spigel D.R;Chih-Hsin Yang;Ciardiello F.; Gridelli C; De Marinis F; Cappuzzo F; Di Maio M; Hirsch F.R; Mok T; Morgillo F; Rosell R; Spigel D.R; CHIH-HSIN YANG; Ciardiello F. |
| 國立臺灣大學 |
2013 |
Epidermal growth factor receptor (EGFR)-mediated adverse events (AEs) in patients (pts) with EGFR mutation positive (EGFR M plus ) non-small cell lung cancer treated with afatinib
|
Yang, J. Chih-Hsin; Sequist, L.; O'Byrne, K.; Schuler, M.; Mok, T.; Geater, S.; Massey, D.; O'Brien, D.; Zazulina, V.; Wu, Y. L.; 楊志新 |
